Bunzl Upgrades 2026 Outlook Amid Strong Performance and Australian Acquisition

Bunzl pre-close statement: 2026 outlook upgraded after stronger first-half trading

Bunzl has used its pre-close statement to tell the market that the first half of 2026 has gone better than previously expected. The headline is simple: trading has been solid enough for management to upgrade its full-year revenue outlook, while also saying profit in the first half should show good year-on-year growth.

That matters because pre-close statements are usually where companies try to keep surprises to a minimum before results. If Bunzl is upgrading guidance here, it is effectively saying momentum has improved and the market needed to know now rather than wait for the half-year figures.

Key numbers from the Bunzl RNS announcement

Metric	Update
First-half 2026 revenue growth	Around 4% at constant exchange rates
Underlying revenue growth	Around 3%
Acquisition contribution to first-half growth	Around 1%, net of disposals
Currency impact on revenue	Relatively neutral at actual exchange rates
First-half adjusted operating profit	Good year-on-year growth at constant exchange rates
First-half operating margin	Up modestly year-on-year
Full-year 2026 revenue guidance	Upgraded
Full-year 2026 operating margin guidance	Unchanged, still expected to be slightly down year-on-year
Scientifix expected revenue	AUD 18 million, around £9 million, in the 12 months to June 2026

Why Bunzl’s upgraded 2026 outlook is a positive signal for investors

The encouraging bit is the mix of growth. Bunzl says first-half revenue should rise by around 4% at constant exchange rates, with around 3% of that coming from underlying revenue growth. Constant exchange rates means stripping out currency movements to show what the business actually did operationally.

That is a decent update because underlying growth is usually the cleaner number. It suggests Bunzl is not relying only on acquisitions or currency swings to make the figures look better.

Management also says growth in the second quarter has been helped by inflation in certain categories, with product-cost increases driven by geopolitical events. That needs a bit of caution. Inflation can lift revenue because companies charge more for the same products, but that is not always as attractive as genuine volume growth.

The better sign is that Bunzl is also seeing encouraging volume growth. In plain English, it is selling more stuff, not just charging more for it. For a distribution business, that is a healthier signal.

North America distribution recovery looks like the real story here

If there is one part of this update that stands out, it is North America. Bunzl says volume growth is expected to be driven by North America, with good growth in its Distribution business.

That matters because management has clearly been working on fixing operational issues there. The company says the business has made operational progress from actions taken, and the chief executive added that responsiveness, agility and high service levels have been largely restored.

That sounds like a business that had been underperforming and is now getting back into shape. For investors, that is important because operational recoveries can do two useful things at once: improve sales and support margins.

Bunzl also says new business wins secured towards the end of last year are helping. That suggests the recent progress is not just temporary catch-up trading, but also reflects contracts or customer gains now feeding into the numbers.

Bunzl profit margins: better in the first half, but still not a perfect picture for the full year

Profitability is good, but not flawless. Bunzl expects good year-on-year growth in adjusted operating profit over the first half at constant exchange rates, and says operating margin should be up modestly year-on-year.

Operating margin is the percentage of revenue left after operating costs, so it is a useful measure of quality as well as scale. A modest improvement is welcome, especially in a distribution group where margins are not usually huge.

However, there is a nuance here. The first-half margin boost is partly due to the net impact of inflation in the second quarter, and Bunzl says much of that is expected to be temporary in nature. It is also benefiting from the annualisation of Nisbets synergies, which means the savings and efficiencies from that acquisition are now feeding through more fully.

So yes, the first-half margin performance looks better. But management has not changed its full-year operating margin guidance, and still expects margin to be slightly down year-on-year. That tells you Bunzl is pleased, but not getting carried away.

Scientifix acquisition in Australia adds to Bunzl’s healthcare and life sciences exposure

The other part of the announcement is the completed acquisition of Scientifix Group in Australia. This is described as a distributor of critical products and services to the Life Sciences and Biotechnology sectors.

Strategically, this makes sense. Bunzl says it expands the category offering of its existing Australian business and fits well with its healthcare operations there. Those are generally attractive end markets because customers tend to value reliability, compliance and service rather than just the lowest possible price.

In revenue terms, it is not a huge deal for the wider group. Scientifix is expected to generate AUD 18 million, around £9 million, in the 12 months to June 2026. The acquisition price was not disclosed.

Still, this looks like classic Bunzl. Small bolt-on acquisitions are part of the playbook, and management says the acquisition pipeline remains active and that 2026 should be an improved year for acquisitions. That reinforces the idea that Bunzl is still using M&A to steadily build market share in fragmented markets.

What looks strongest and what still needs watching in Bunzl shares

What looks positive

• Full-year 2026 revenue guidance has been upgraded.
• First-half revenue growth of around 4% includes around 3% underlying growth, which is a decent quality signal.
• North America Distribution appears to be recovering operationally.
• First-half adjusted operating profit and operating margin are both expected to improve year-on-year.
• The acquisition strategy remains active, with Scientifix adding to healthcare and life sciences exposure.

What looks less convincing

• Some of the growth is being helped by inflation linked to geopolitical events, and management says much of that margin effect is temporary.
• Full-year operating margin guidance is unchanged and still expected to be slightly down year-on-year.
• The acquisition is strategically sensible, but small in revenue terms for a group of Bunzl’s size.
• Macroeconomic and geopolitical uncertainties are still flagged by management.

My view on this Bunzl RNS: better than expected, but still measured

This is a good update. Not flashy, not transformational, but good in the way long-term Bunzl investors usually like. The most important part is probably the combination of improved underlying growth, operational recovery in North America, and enough confidence to upgrade full-year revenue guidance.

The main note of caution is that not all of the first-half strength looks permanent. Inflation is helping, and the company is openly saying some of that benefit should fade. On top of that, Bunzl is still guiding to a slightly lower operating margin for the full year.

Even so, this reads like a business that is moving in the right direction. The North America recovery looks real, acquisitions are back on the agenda, and management’s tone is confident without sounding reckless. For retail investors, that is usually a decent combination.

The next step is seeing whether Bunzl can turn this stronger first-half trading into sustained profit growth, rather than just a better quarter helped by inflation and easier comparisons. For now, though, this RNS lands on the positive side.